Cocrystal Pharma, Inc. announced that the last subject has been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections. The randomized, double-blind, placebo-controlled trial was conducted at Emory University School of Medicine using healthy subjects infected with the norovirus GII.2 strain. Preliminary efficacy results are expected in late 2026 or early 2027. CDI-988 is an oral antiviral designed to inhibit viral replication and has previously demonstrated safety in Phase 1 trials. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics.

On August 12, 2026, the Board of Directors appointed Carol L. Brosgart as a director effective immediately. No arrangements or understandings exist between Ms. Brosgart and other persons regarding her selection, there are no family relationships with existing directors or executive officers, and no related party transactions require disclosure. Cocrystal Pharma, Inc. operates in the biotechnology industry, focusing on the discovery and development of antiviral drugs.

Cocrystal Pharma, Inc. announced the appointment of Carol L. Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings extensive experience in antiviral therapy and biopharma advisory, having contributed to FDA-approved therapies at Gilead Sciences and served on boards at Galmed Pharmaceuticals and Eradivir Biotech. Her appointment aims to provide clinical insights for advancing the development of CDI-988 for norovirus and the broader antiviral pipeline. Cocrystal Pharma is a clinical-stage biotechnology company developing novel antiviral therapeutics targeting noroviruses, influenza, coronaviruses, and hepatitis C.

Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement on July 31, 2026, to sell 5,474,053 shares of common stock to OPKO Health, Inc., for gross proceeds of $5.0 million at $0.9134 per share. The transaction was conducted as an unregistered private placement under Regulation D. Proceeds will fund preclinical and clinical drug candidate programs, general corporate purposes, and working capital. Cocrystal Pharma is a biotechnology company developing novel antiviral therapeutics for norovirus, influenza, coronaviruses, and hepatitis C.

Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer, effective June 3, 2026. Mr. Sapirstein's compensation package includes an annual base salary of $265,000, a 50% performance bonus target, and an initial grant of 235,000 stock options with a $1.05 exercise price. He replaces Co-CEOs Sam Lee and James Martin, who will remain in their roles as President/Chief Scientific Officer and Chief Financial Officer, respectively. Cocrystal Pharma, Inc. is a biopharmaceutical company.